Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment.
about
Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventionsPalbociclib: an evidence-based review of its potential in the treatment of breast cancerThe molecular balancing act of p16(INK4a) in cancer and aging.The retinoblastoma tumor suppressor pathway modulates the invasiveness of ErbB2-positive breast cancer.Carcinoma initiation via RB tumor suppressor inactivation: a versatile approach to epithelial subtype-dependent cancer initiation in diverse tissues.RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer.Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis.RB116: an RB1+ retinoblastoma cell line expressing primitive markers.Regulation of miR106b cluster through the RB pathway: mechanism and functional targets.Retinoblastoma and phosphate and tensin homolog tumor suppressors: impact on ductal carcinoma in situ progressionCo-Expression of p16, Ki67 and COX-2 Is Associated with Basal Phenotype in High-Grade Ductal Carcinoma In Situ of the BreastDNA methylation in ductal carcinoma in situ of the breast.EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer.Induction of fibroblast senescence generates a non-fibrogenic myofibroblast phenotype that differentially impacts on cancer prognosisStromal p16 expression is significantly increased in malignant ovarian neoplasms.p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer.Stromal p16 expression is significantly increased in endometrial carcinoma.P16 but not retinoblastoma expression is related to clinical outcome in no-special-type triple-negative breast carcinomas.Ductal carcinoma in situ - update on risk assessment and management.The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness.Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis.p16Ink4a and p21Cip1/Waf1 promote tumour growth by enhancing myeloid-derived suppressor cells chemotaxis.HPV Status and Its Correlation with BCL2, p21, p53, Rb, and Survivin Expression in Breast Cancer in a Chinese Population.Three-dimensional reconstruction of ductal carcinoma in situ with virtual slides.
P2860
Q27022834-7B1BCAD6-677F-44C1-82A2-5D67488AFC9FQ34027724-4BB15B94-A4B8-4E7C-BB44-2E30E774DE45Q34038585-F68C64DA-A635-450A-816D-FFA7C6E5CFB0Q34115095-1F033870-5732-4E3A-B320-C7ADCDE149F8Q35061054-4C64040C-39B1-4DEC-A620-38AB45A2F9DEQ35157633-7569D14F-0F30-4F07-92D3-7040268CA1BBQ35620241-A8FA89AE-953F-4897-9D6A-910D10548BF6Q36130090-13BAB904-7B11-4832-B582-C99AC04ED174Q36338756-14E87AF3-683F-4595-B9C6-42B347EEFF76Q36458932-170923EE-C1B7-46FB-8821-1F173DF8CAE9Q36604665-A86B36E0-33AC-483D-B58A-74F1DA2AA431Q36727409-B266D165-05ED-4641-8430-3A1C30CD6628Q36914879-ABD0E881-7793-4EFA-B95D-1E65AE863445Q36998647-4E7F0633-1DB8-4382-86AA-093353189B4AQ37079757-F811893F-75D9-4E3D-A7A3-B70957C82389Q37643500-5DDA0D9C-137F-4765-AE35-61111E691DB4Q37662109-3A87C995-C636-4E43-873C-B9D76980303FQ37697156-A195E784-B643-4B17-991A-98E767A9D56EQ37706263-E9663379-4B8E-4606-BE6C-9ED9BD3CE5E6Q38395549-28B340FD-CA99-4767-804C-58FA42DFE78BQ38696796-D9C381E5-119D-4083-BE8B-AE4B62CE351DQ38962238-EFC71FD3-E4B3-49EF-ABBA-819C617D99F9Q39048659-67855C36-23F4-4A56-A30A-877E0D1D87DEQ46699535-B3FB7932-027D-4B24-962D-B8F15773CB70Q47113842-63AA237C-A334-4505-8C78-37860E06EB2DQ49199308-1BD35B16-F7E3-4B55-B27D-A368804B08BEQ52838790-9EC3D0CC-0A7D-497F-9F5A-96D62779353A
P2860
Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Association of RB/p16-pathway ...... ersus tissue microenvironment.
@ast
Association of RB/p16-pathway ...... ersus tissue microenvironment.
@en
type
label
Association of RB/p16-pathway ...... ersus tissue microenvironment.
@ast
Association of RB/p16-pathway ...... ersus tissue microenvironment.
@en
prefLabel
Association of RB/p16-pathway ...... ersus tissue microenvironment.
@ast
Association of RB/p16-pathway ...... ersus tissue microenvironment.
@en
P2093
P2860
P1476
Association of RB/p16-pathway ...... ersus tissue microenvironment.
@en
P2093
Adam Ertel
Agnieszka K Witkiewicz
Dayana B Rivadeneira
Erik S Knudsen
Gordon F Schwartz
Jessica Kline
Paolo Fortina
Terry Hyslop
P2860
P304
P356
10.1016/J.AJPATH.2011.05.043
P407
P577
2011-07-12T00:00:00Z